Dun-Quan Xu

880 citations
25 papers · 751 indexed · h-index 19
Topics
Pulmonary Hypertension Research and Treatments (7 papers)Traditional Chinese Medicine Analysis (5 papers)Eicosanoids and Hypertension Pharmacology (4 papers)
Partner nations
ChinaRussia

In The Last Decade

Dun-Quan Xu

25 papers receiving 747 citations

Peers

Dun-Quan Xu
Comparison fields: 5 of 85
  • Molecular Biology 267
  • Pulmonary and Respiratory Medicine 261
  • Immunology 115
  • Complementary and alternative medicine 86
  • Physiology 83
Replace Erez Scapa with:
Erez Scapa Israel
Zheng Xu China
Jenna L. Betters United States
Takehiro Fujise Japan
Zhenning Liu China
Susana Vallejo Spain
Yingqing Chen China
Zheng Zhao China
Lucas Opazo-Ríos Spain
Yong-liang Jia China
Dun-Quan Xu relative to Erez Scapa Israel Erez Scapa's profile →
Citations per field
00.5×2.8×
Erez Scapa · 1×
Citations per year

Countries citing papers authored by Dun-Quan Xu

Since Specialization
Citations

This map shows the geographic impact of Dun-Quan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dun-Quan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dun-Quan Xu more than expected).

Fields of papers citing papers by Dun-Quan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dun-Quan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dun-Quan Xu. The network helps show where Dun-Quan Xu may publish in the future.

Co-authorship network of co-authors of Dun-Quan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Dun-Quan Xu. A scholar is included among the top collaborators of Dun-Quan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dun-Quan Xu. Dun-Quan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 12
2 91
3 16
4 1
5 44
6 42
7 47
8 12
9 33
10 16
11 44
12 27
13 22
14 42
15 10
16 38
17 35
18 21
19 24
20 40

About Dun-Quan Xu

Dun-Quan Xu is a scholar working on Biochemistry, Complementary and alternative medicine and Cancer Research, having authored 25 papers that have together received 751 indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (7 papers), Traditional Chinese Medicine Analysis (5 papers) and Eicosanoids and Hypertension Pharmacology (4 papers). The work is most often cited by research in Complementary and alternative medicine (86 citations), Biochemistry (69 citations) and Pulmonary and Respiratory Medicine (261 citations). Dun-Quan Xu has collaborated with scholars based in China and Russia. Frequent co-authors include Zhichao Li, Haiying Dong, Ying Luo, Mingqing Dong, Pengtao Zhao, Wen Niu, Yanxia Wang, Manling Liu, Man-Ling Liu and Bo Zhang. Their work appears in journals such as PLoS ONE, Free Radical Biology and Medicine and European Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026